Our support
We support by providing advice, community, and funding to accelerate the development of your innovation. We focus on the development of new treatments and interventions that help reduce the prevalence and impact of Antimicrobial Resistance (AMR).
Funding
Up to €250,000 in non-dilutive funding will be provided to selected projects to help answer critical questions needed to develop business and translational plans to convince investors at the next funding stage.
Community
Our community of industry professionals, academic experts, entrepreneurs, policymakers, investors, public health employees, and health care providers shares ideas and fights drug-resistant bacterial infections together.
Advice
Our partners provide advice on early alignment with medical needs and market demand, the development of a quality translational path, and entrepreneurship.
Support stages
We provide advice and community to innovators developing therapeutics for human infectious diseases. You may ask for advice on any R&D or funding matter. When ready, you can apply to stage I for more detailed feedback from Industry partners and funding up to €10k to refine the business case. Projects selected for Stage II receive up to €250k and further support to build a company ready for the next stage of investment.
Who do we help
INCATE welcomes applications from early-stage ventures worldwide who are ready to commercialize new therapy concepts for combating AMR. Applications are open to ventures in the seed stage or even earlier, including academic groups.
